Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion (ETERNAL-LVO)

CONDITION

Stroke

GENDER

Both males and females

AGE GROUP

From 18

and above

STATUS

Recruiting

Patients presenting to the emergency department with an acute ischemic stroke due to a large vessel occlusion eligible for thrombectomy and target mismatch on computed tomography perfusion imaging within 24 hours of onset will be assessed determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.

CONTACT DETAILS

Clinical Trial Site: Northeast Health Wangaratta (NHW) Clinical Trials Research
Phone Number: 03 5722 5521 Email: research@nhw.org.au Location: 35-47 Green St, Wangaratta VIC, Australia

Studies Contact Form

  • Hidden

Approved By: Melbourne Health Human Research Ethics Committee              

Clinical Trial Registry Link: Click Here